Benefits
Lower self-reported joint pain scores in people who already had joint pain (one 60-day trial)
In one randomized, double-blind, placebo-controlled trial, 80 adults averaging 50 years of age who had mild to moderate joint pain for at least three months took either 20 mg a day of Q-Actin® or a rice protein placebo for 60 days. The Q-Actin® group improved 31.79% on the WOMAC joint questionnaire and 32.39% on the Pain Disability Index, and did significantly better than placebo on the Brief Pain Inventory. Those numbers need to be read next to what the placebo group did: it got worse, by 14.30% on WOMAC and 14.96% on the Pain Disability Index. Placebo groups in joint pain studies usually improve at least somewhat, so a placebo group that declines over 60 days is unusual and it widens the difference between the two groups. The trial was in people who already had joint pain, so nothing here speaks to preventing joint problems in healthy joints. It is also a single study, published in Cureus, a journal whose peer review is lighter than that of specialist joint and rheumatology journals.
Proposed anti-inflammatory action (laboratory work only, not measured in people)
This is a proposed explanation rather than something anyone measured in a person. Laboratory work on idoBR1, the marker Q-Actin® is standardized to, reports reduced inflammatory signals such as TNF-alpha, IL-6 and nitric oxide in cell experiments. No inflammation markers were measured in the 80 people who took part, and comparing the extract to how anti-inflammatory drugs work is not supported by any study of this product. The cucurbitacin and hydroxycinnamic acid content described here is not the standardization used in the cited trial, which specified more than 1% idoBR1, so treat these compound-level claims as background chemistry rather than evidence for the product.
Self-reported daily-function questionnaire scores
The trial did not measure range of motion or run any physical performance test. What it used were four questionnaires that participants filled in about themselves: WOMAC, the Lequesne Functional Index, the Brief Pain Inventory and the Pain Disability Index. WOMAC, which asks about stiffness and everyday activities as well as pain, and the Pain Disability Index both improved in the Q-Actin® group over 60 days, while the same scores worsened in the placebo group. That is a change in how people rated their own pain and daily activities, not a measured change in joint structure or movement.
Mechanism of action
How cucumber extract is thought to work (cell and test tube evidence)
The mechanism here comes from laboratory work, not from people. Cell experiments on idoBR1, the iminosugar Q-Actin® is standardized to, report reduced inflammatory signals including TNF-alpha, IL-6, nitric oxide and NF-kappaB activity in cells exposed to a bacterial toxin. Details such as COX-2 or 5-LOX inhibition, prostaglandin changes and antioxidant activity are described for cucumber compounds in test tube research and were not tested in the trial, which measured only questionnaire scores. Treat all of this as a possible explanation, not a demonstrated one, and note that nothing here shows any effect on joint breakdown over time.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Q-Actin® at 20 mg a day against a rice protein placebo for 60 days, in adults with mild to moderate joint pain, using four validated self-report questionnaires. This trial is peer reviewed and published, in Cureus (2025), and it names the branded product itself rather than a generic cucumber extract, which is a genuine strength. The limits are that Cureus has a lighter peer-review process than most clinical journals, and that this is the only study cited on the page, so any claim beyond what it measured is uncited.
80 adults (mean age 50.10) with mild-to-moderate joint pain (>3 months history). Randomized, double-blind, placebo-controlled trial; 20 mg/day Q-actin™ (Cucumis sativus L. standardized to >1% idoBR1 iminosugar) or a rice protein placebo for 60 days. NCT06246383 (Jacksonville University). Funded in part by Gateway Health.
Over 60 days the Q-Actin® group improved 31.79% on WOMAC and 32.39% on the Pain Disability Index, with a significant between-group difference on the Brief Pain Inventory. The Lequesne Functional Index was also used. The placebo group moved in the opposite direction, worsening 14.30% on WOMAC and 14.96% on the Pain Disability Index. A placebo group that deteriorates is unusual in joint pain research, where placebo arms typically improve, and it makes the difference between groups larger than it would otherwise be. Every outcome was a self-reported questionnaire. An earlier head-to-head comparison against glucosamine and chondroitin is sometimes mentioned for this ingredient, but no such study is cited on this page, so it should not be counted as evidence here. The idoBR1 anti-inflammatory findings come from cell experiments using a bacterial toxin, not from the people in this trial, and no inflammatory markers were measured in the participants. The dose that was tested is 20 mg a day, which is very small for a joint product and is worth naming for that reason.